HIPRA Biotech Services is expanding its biologics manufacturing capacity to support supply chain resilience with a new a GMP microbial fermentation facility, a new R&D building and Quality Control labs.

With over 200,000 square meters of owned land at its integrated campus, HIPRA Biotech Services offers pharma and biopharma clients expansion flexibility. The company recently launched a new R&D building to accelerate process development and innovation and is commissioning a GMP microbial fermentation facility with several 2,000L scale fermenters to meet rising clinical and commercial demand. 

Additionally, new QC labs are scheduled to break ground in 2026, reinforcing quality and regulatory infrastructure. Also, an advanced shell building is being built out for future 2,000L single-use mammalian cell culture GMP facility, ensuring scalable capacity across modalities.

These facilities complement the company’s GMP aseptic fill-finish operations, creating a fully integrated drug substance and drug product platform. Under a unified quality system with a strong regulatory track record, the company aims to deliver seamless clinical-to-commercial continuity.

“Critically, our strategy emphasizes proactive capacity development, —ensuring warm and hot manufacturing readiness ahead of client demand. This approach provides resilience against geopolitical shifts, tariff risk, and supply chain disruption, while enabling portfolio specialization in high-value biologics,” said Eduard Viladesau, Managing Director of HIPRA Biotech Services. “We are not simply expanding facilities, we are building capacity, certainty, and partnership for the future of biologics manufacturing.”

HIPRA Biotech Services is deploying advanced single-use technologies, modern technology platforms, and scalable infrastructure to support next-generation oncology, immunology, and rare disease therapies from early development through commercial supply.